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Comparative efficacy of a single oral dose of ondansetron and of
buspirone against cisplatin-induced emesis in cancer patients
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Sumnary Buspirone, an agonist of the 5-HTIA subtype of serotonin receptors, has shown antiemetic activity
in animal models. However, in cancer patients treated with cisplatin, ondansetron, given either i.v. (one 8-mg
dose 30min after cisplatin) or orally (one 16-mg dose at the end ofcisplatin infusion) was superior (P<0.001)
to buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later), in all parameters of antiemetic
efficacy. These results are in favour of 5-HT3 receptors, but against the participation of 5-HTIA receptors in
acute emesis associated with cisplatin chemotherapy.
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Serotonin plays an important role in the pathogenesis of
nausea and vomiting (Cubeddu et al., 1990, 1992; Andrews
and Davis, 1993). Emesis induced by anti-cancer chemo- and
radiotherapy, post-operative emesis and ipecac-induced
emesis are ameliorated by selective antagonists of 5-HT3
receptors (see Andrews and Davis, 1993, and Andrews, 1994,
for review). Recent studies indicate that, in addition to 5-
HT3 receptors, other serotonin receptor subtypes may play a
role in emesis. In laboratory animals, activation of 5-HTlA
receptors by a single dose of 8-hydroxy-2-(di-n-propyl
amino)tetralin(8-OH-DPAT), buspirone or other 5-HTIA
agonists suppresses emesis induced by motion sickness, cisp-
latin, ac2-adrenergic receptor agonists, nicotine, veratrine, cop-
per sulphate or stimulation of vagal afferents (Lucot and
Crampton, 1987, 1989; Milano and Gregot, 1992; Okada et
al., 1994). The antiemetic effects of 5-HTlA receptor agonists
have not been explored in humans. In this study, we inves-
tigated the antiemetic effect of buspirone, an agonist of 5-
HT1A receptors, in human cancer patients treated with cisp-
latin.
Recent studies designed to simplify treatment and to
reduce pharmacy and nursing costs related to antiemetic
therapy demonstrated that ondansetron can be given in a
single i.v. dose with no loss of its antiemetic efficacy (Beck et
al., 1992; Seynaeve et al., 1992). Although oral ondansetron
has been used for non-cisplatin chemotherapies (Cubeddu et
al., 1994), no information is available on whether oral
ondansetron could control emesis associated with cisplatin
treatment. The antiemetic efficacy of one i.v. and of one oral
dose of ondansetron was compared with that of oral bus-
pirone. Dose administration was timed to achieve highest
antiemetic levels at the peak of emesis.
Patients and methods
Design
A three-arm, randomised, double-blind, parallel group study
design was employed. One group received a single 8 mg i.v.
dose of ondansetron, dissolved in 50ml of D5/W (dextrose
5% in water), and given as a 15 min infusion, starting 30 min
after completing the 1 h cisplatin infusion. Another group of
patients received a single 16 mg dose of ondansetron
administered orally at the end of the cisplatin infusion. The
buspirone group received two oral doses of buspirone, one
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60 mg dose at the end of the cisplatin infusion and a second
60 mg dose administered 30 min later. Cisplatin was given in
a 1 h i.v. infusion. To avoid additional variability in the
emetic response induced by cytotoxics other than cisplatin,
only etoposide and/or 5-fluorouracil were allowed as
associated chemotherapeutic drugs. Rescue antiemetic con-
sisted of an 8 mg i.v. dose of ondansetron, dissolved in 50ml
of D5/W, and given as a 15 min infusion.
For the double-blind design, placebo-matched oral
ondansetron and buspirone were available. Saline was used
as placebo for i.v. ondansetron. For example, patients ran-
domised to receive buspirone received, in addition to bus-
pirone, two tablets ofplacebo-matched oral ondansetron and
a 15 min i.v. infusion of 4ml of saline diluted in 50 ml of
D5/W.
Patients
A total of 28 chemotherapy-naive patients, 18 years of age or
older, who had not received previous chemotherapy and had
a Karnofsky performance score of at least 60% were enrolled
in the study. No study patients received any antiemetic
medication 24 h before the first dose of any of the study
drugs. In addition, patients who received abdominal or pelvic
radiation within 72 h before or during the study period were
excluded.
Antiemetic efficacy
The total number of emetic episodes, the need for rescue
antiemetics and time to the onset of emesis were calculated
for the 1 day study period. An emetic response was defined
as a single vomit or retch or any number of continuous
vomits and/or retches. Treatment response categories over
the 24 h study period were defined as: complete response (no
emetic episodes), major response (1-2 emetic episodes),
minor response (3-4 emetic episodes), and failure () 5
emetic episodes). Failure also included needing rescue
therapy.
Statistical assessment
The Mantel-Haenszel test was used to compare each
ondansetron group with buspirone, and to compare oral and
intravenous ondansetron, with respect to complete response
rates, complete plus major response rates and failure rates.
The Wilcoxon rank sum test was used to compare the
number of emetic episodes and the time to the first emetic
episode. No adjustments for multiple comparisons were plan-
ned or performed. All tests were two-sided at significance
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Results
The demographics characteristic of the patients are shown in
Table I. Patients were similar with regard to age, weight and
dose of cisplatin administered to the three study groups.
However, a higher proportion of females was present in the
oral ondansetron-treated group (P<0.01, based on the chi-
square test).
Results for the control of acute emesis are shown in Table
II and Figure 1. In pairwise treatment comparisons, both
single dose oral and single dose i.v. ondansetron were statis-
tically superior to buspirone for all measured efficacy
parameters. Compared with buspirone, patients treated with
a single dose of oral or i.v. ondansetron experienced a greater
proportion of complete treatment responses (i.e. no emesis)
(P<0.01), fewer emetic episodes (P<0.01) and a lower pro-
portion of treatment failures (P<0.01). Further, the number
of patients requiring rescue antiemetic was significantly
greater after buspirone than after either of the ondansetron
treatments (Figure 1). There were no differences in the
measurements of antiemetic efficacy between oral ondanset-
ron and i.v. ondansetron. Ondansetron (8 mg i.v.), given as
rescue antiemetic, effectively controlled vomiting in
buspirone-treated patients, since there were no additional
emetic episodes after its administration.
Discussion
Recent studies in laboratory animals indicate that 5-HTlA
receptor agonists (buspirone, 8-OH-DPAT, flesinoxan, gen-
pirone) have antiemetic activity against emetic stimuli acting
via different pathways (Lucot and Crampton, 1987, 1989;
Milano and Gregot, 1992; Okada et al., 1994). High concen-
trations of 5-HTlA binding sites and of receptor mRNA
have been found in the nucleus tractus solitarius, an impor-
tant brain area in the control of emesis (Lucot, 1992).
Although part of the antiemetic action of 5-HTIA agonists
observed in animals may be mediated through the nucleus
tractus solitarius, it is possible that these agents could act at
the vomiting centre. In this study, we explored whether bus-
pirone, a 5-HTIA agonist with anxiolytic properties, was
effective against cisplatin-induced emesis in cancer patients.
Buspirone is completely absorbed after oral administration,
peak plasma levels are achieved within 40-90 min of dosing
and elimination half-life averages 4 h. Recommended initial
dosage for anxiolytic effects is of 10-15 mg day-' and
maintenance dosage of 15-30 mg day-1, given in 2-3
divided doses. The manufacturer recommends not to exceed
Table I Patient demographics
Buspirone i.v. ondansetron Oral ondansetron
No. of patients 10 9 9
Age 51 ±3 45±5 48±5
Sex (M:F) 7:3 8:1 2:7
Weight (kg) 59 2 62± 3 63 ± 3
Cisplatin dose 81 ± 4 89 ± 4 85 ± 4
Table II Comparative antiemetic activity of buspirone and
ondansetron
Treatment Buspirone i.v. ondansetron Oral ondansetron
responses (n = 10) (n = 9) (n = 9)
Complete 0 (0%) 6 (67%)a 5 (56%)b
Major 1 (10%) 2 (22%) 3 (33%)
Minor 3 (30%) 1 (11%) I (11%)
Failure 6 (60%) 0 (0%)C 0 (O%)C
Complete response, no emetic episodes; major, one or two emetic
episodes; minor, three or four emetic episodes; failure, > 5 emetic
episodes or administration of rescue antiemetics. Significantly
different from buspirone at ao.002, b0.008 and c0.006. P-values are
based on Mantel-Haenszel test for complete response and for
failures.
60 mg day ' (see American Hospital Formulary Services,
1993 for review). In this study, buspirone, in doses much
higher than required for anxiolytic activity failed to protect
cancer patients from the acute (initial 24 h) emetic action of
cisplatin. The complete, major and minor response rates and
the failure rates in buspirone-treated patients were similar to
those previously described for placebo-treated patients
(Cubeddu et al., 1990). These results suggest that buspirone
at the dose-regimen employed (three to four times higher
than the daily doses required for anxiolytic effects) is devoid
of clinically significant antiemetic activity against the
cisplatin-induced emesis. The lack of effect of buspirone
could be explained by the reported differences in the degree
of involvement of 5-HT1A receptors in emesis, within
species. For example, buspirone was less effective in the ferret
than in the cat against cisplatin-induced emesis (Wells et al.,
1993). Our study suggests that the drug may not be very
effective in humans. Additional studies on repeated (or even
higher) doses of buspirone on cisplatin-induced acute and
delayed emesis (we only evaluated acute emesis) and on
nausea and emesis associated with other chemotherapeutic
drugs are required.
Intravenous ondansetron, given either in repeated doses or
as a continuous infusion, antagonises vomiting associated
with cisplatin treatment (Cubeddu et al., 1990; Beck et al.,
1992; Seynaeve et al., 1992). These regimens have high phar-
macy and nursing costs, and often lengthen the duration of
hospitalisation. Recent studies showed that a single 8 mg i.v.
dose of ondansetron was as effective as the more complicated
regimens (Beck et al., 1992; Seynaeve et al., 1990). Although
our study is based on a small number of patients, the com-
plete response (67%), complete plus major response (89%)
and the failure (0%) rates obtained in this trial with a single
8 mg i.v. dose of ondansetron (given 30 min after cisplatin)
were similar to those observed by Beck et al. (1992), employ-


















Figure 1 Need for rescue antiemetics after prophylactic treat-
ment with buspirone or ondansetron in patients treated with
cisplatin chemotherapy. The percentage of patients requiring res-
cue antiemetics after cisplatin-based chemotherapy over the 24 h
study period for each of the three treatment groups is shown.
Both ondansetron groups were significantly different from bus-
pirone (P<0.01) based on Mantel-Haenszel test. L=, Bus-
pirone; 1B, ondansetron.
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The antiemetic efficacy of a single oral dose of ondanset-
ron against moderate to high-dose cisplatin had not been
studied. In previous trials, repeated doses of oral ondanset-
ron were administered only after an i.v. loading dose of 8 mg
(see Cooke and Mehra, 1994 for review). Since the
bioavailability of oral ondansetron is nearly 50%, the oral
dose of ondansetron employed in this study was twice the i.v.
dose. In addition, oral ondansetron was given at the end of
the cisplatin infusion, to achieve higher levels at the time of
the emesis peak. In this work, oral ondansetron proved as
effective as i.v. ondansetron, indicating that a single pro-
phylactic 16 mg oral dose of ondansetron can be used to
cover effectively the period of acute emesis associated with
cisplatin treatment.
In summary, in this study we demonstrated that the acute
period of emesis associated with cisplatin chemotherapy, can
be treated either with one oral or one i.v. dose of ondanset-
ron. These simplified regimens facilitate compliance and
reduce cost and patient discomfort. However, further studies
in larger numbers of patients are required to determine
whether a single 16 mg oral dose of ondansetron (8 mg i.v.)
was highly effective in stopping vomiting when administered
as rescue antiemetic. Finally, acute dosing with oral bus-
pirone did not protect against acute emesis induced by cisp-
latin. Our results support the role of 5-HT3 receptors but are
against the participation of 5-HTIA receptors in acute emesis
associated with treatment using cisplatin in cancer
patients.
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